{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:05:28Z","timestamp":1787061928585,"version":"build-2736575974"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:p>\n                    Atopic dermatitis (AD) is a common chronic allergic skin disease characterized clinically by severe skin lesions and pruritus.\n                    <jats:italic>Portulaca oleracea<\/jats:italic>\n                    L. (PO) is a resourceful plant with homologous properties in medicine and food. In this study, we used two different methods to extract PO, and compared the therapeutic effects of PO aqueous extract (POAE) and PO ultrasound-assisted ethanol extract (POEE) on 2,4-dinitrochlorobenzene (DNCB)-induced AD mice. The results showed that in POAE and POEE, the extraction rates of polysaccharides were 16.95% and 9.85%, while the extraction rates of total flavonoids were 3.15% and 3.25%, respectively. Compared with AD mice, clinical symptoms such as erythema, edema, dryness and ulceration in the back and left ear were alleviated, and pruritus behavior was reduced after POAE and POEE treatments. The thickness of the skin epidermis was thinned, the density of skin nerve fibers labeled with protein gene product 9.5 (PGP9.5) was decreased, and mast cell infiltration was reduced. There was a decrease in blood lymphocytes, eosinophils and basophils, a significant decrease in spleen index and a noticeable decrease in serum immunoglobulin E (Ig E). POEE significantly reduced the concentration of the skin pruritic factor interleukin (Il)-31. POAE and POEE reduced the concentration of skin histamine (His), down-regulated mRNA expression levels of interferon-\u03b3 (Ifn\u03b3), tumor necrosis factor-\u03b1 (Tnf-\u03b1), thymic stromal lymphopoietin (Tslp) and Il-4, with an increase of Filaggrin (Flg) and Loricrin (Lor) in skin lesions. These results suggested that POAE and POEE may inhibit atopic response and alleviate the clinical symptoms of AD by inhibiting the expression of immune cells, inflammatory mediators and cytokines. PO may be a potential effective drug for AD-like diseases.\n                  <\/jats:p>","DOI":"10.3389\/fnut.2022.986943","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T01:40:42Z","timestamp":1660614042000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Portulaca oleracea L. extracts alleviate 2,4-dinitrochlorobenzene-induced atopic dermatitis in mice"],"prefix":"10.3389","volume":"9","author":[{"given":"Wei-jie","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-pei","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-bo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-ning","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(06)69283-0","article-title":"Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys.","volume":"368","author":"Asher","year":"2006","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19103086","article-title":"New cytokines in the pathogenesis of atopic dermatitis-new therapeutic targets.","volume":"19","author":"Klonowska","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: summary of a report for the National Eczema Association.","volume":"137","author":"Drucker","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies.","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s12016-015-8486-7","article-title":"Treatment of eczema: corticosteroids and beyond.","volume":"51","author":"Chong","year":"2016","journal-title":"Clin Rev Allergy Immunol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12787","article-title":"What\u2019s new in the treatment of atopic dermatitis?","volume":"32","author":"Dattola","year":"2019","journal-title":"Dermatol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis.","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/jdv.15973","article-title":"Neuroimmune interactions in chronic itch of atopic dermatitis.","volume":"34","author":"Yosipovitch","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jaad.2013.01.019","article-title":"Chinese herbal medicine for atopic dermatitis: a systematic review.","volume":"69","author":"Tan","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jep.2014.11.018","article-title":"Use of traditional Chinese medicine reduces exposure to corticosteroid among atopic dermatitis children: a 1-year follow-up cohort study.","volume":"159","author":"Chen","year":"2015","journal-title":"J Ethnopharmacol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2020.126621","article-title":"Phytochemical composition and nutritional value of different plant parts in two cultivated and wild purslane (Portulaca oleracea L.) genotypes.","volume":"320","author":"Nemzer","year":"2020","journal-title":"Food Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.biopha.2017.09.142","article-title":"Study of the non-clinical healing activities of the extract and gel of Portulaca pilosa L. in skin wounds in wistar rats: a preliminary study.","volume":"96","author":"Alves Barros","year":"2017","journal-title":"Biomed Pharmacother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0378-8741(03)00194-6","article-title":"Simple evaluation of the wound healing activity of a crude extract of Portulaca oleracea L. (growing in Jordan) in Mus musculus JVI-1.","volume":"88","author":"Rashed","year":"2003","journal-title":"J Ethnopharmacol."},{"key":"B14","first-page":"715","article-title":"[Experimental studies of geroprotective and anti-aging effects of chemical compounds of Portulaca oleracea L. (review).].","volume":"34","author":"Berezutsky","year":"2021","journal-title":"Adv Gerontol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1248\/bpb.b18-00349","article-title":"Effects of supplementary seleno-L-methionine on atopic dermatitis-like skin lesions in mice.","volume":"41","author":"Arakawa","year":"2018","journal-title":"Biol Pharm Bull."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/nu12010249","article-title":"Fermented Morinda citrifolia (Noni) alleviates DNCB-induced atopic dermatitis in NC\/Nga mice through modulating immune balance and skin barrier function.","volume":"12","author":"Kim","year":"2020","journal-title":"Nutrients."},{"key":"B17","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/0091-6749(90)90079-J","article-title":"Thymopentin therapy reduces the clinical severity of atopic dermatitis.","volume":"85","author":"Leung","year":"1990","journal-title":"J Allergy Clin Immunol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.114021","article-title":"Efficacy and action mechanisms of a Chinese herbal formula on experimental models of atopic dermatitis.","volume":"274","author":"Wang","year":"2021","journal-title":"J Ethnopharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0014-2999(03)01828-4","article-title":"Analysis of the spontaneous scratching behavior by NC\/Nga mice: a possible approach to evaluate antipruritics for subjects with atopic dermatitis.","volume":"471","author":"Takano","year":"2003","journal-title":"Eur J Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12090789","article-title":"Advanced characterization of imiquimod-induced psoriasis-like mouse model.","volume":"12","author":"Jabeen","year":"2020","journal-title":"Pharmaceutics."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00267-021-01456-z","article-title":"Multipurpose benefits of an underexplored species purslane (Portulaca oleracea L.): a critical review.","author":"Srivastava","year":"2021","journal-title":"Environ Manage."},{"key":"B22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jep.2017.05.004","article-title":"A review of traditional uses, phytochemistry and pharmacology of Portulaca oleracea L.","volume":"205","author":"Iranshahy","year":"2017","journal-title":"J Ethnopharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.phytochem.2019.02.009","article-title":"Metabolomics driven analysis of 11 Portulaca leaf taxa as analysed via UPLC-ESI-MS\/MS and chemometrics.","volume":"161","author":"Farag","year":"2019","journal-title":"Phytochemistry."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.841397","article-title":"Portulaca oleracea polysaccharides modulate intestinal microflora in aged rats in vitro.","volume":"13","author":"Fu","year":"2022","journal-title":"Front Microbiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.jep.2016.10.082","article-title":"The influence of hydro-ethanolic extract of Portulaca oleracea L. on Th\/Th balance in isolated human lymphocytes.","volume":"194","author":"Askari","year":"2016","journal-title":"J Ethnopharmacol."},{"key":"B26","first-page":"409","article-title":"Modulation of lung inflammation and immune markers in asthmatic rats treated by Portulaca oleracea.","volume":"7","author":"Kaveh","year":"2017","journal-title":"Avicenna J Phytomed."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112148","article-title":"Immunomodulatory assessment of Portulaca oleracea L. extract in a mouse model of colitis.","volume":"143","author":"Alfwuaires","year":"2021","journal-title":"Biomed Pharmacother."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57121387","article-title":"Topical application of galgeunhwanggeumhwangryeon-tang recovers skin-lipid barrier and ameliorates inflammation via filaggrin-thymic stromal lymphopoietin-interleukin 4 pathway.","volume":"57","author":"Ahn","year":"2021","journal-title":"Medicina (Kaunas)."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.735295","article-title":"The anti-inflammatory and anti-pruritus mechanisms of Huanglian jiedu decoction in the treatment of atopic dermatitis.","volume":"12","author":"Xu","year":"2021","journal-title":"Front Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.jaci.2019.12.899","article-title":"How does parental history of atopic disease predict the risk of atopic dermatitis in a child? A systematic review and meta-analysis.","volume":"145","author":"Ravn","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.jaip.2020.02.022","article-title":"Endophenotypic variations of atopic dermatitis by age, race, and ethnicity.","volume":"8","author":"Nomura","year":"2020","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B32","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.tim.2017.11.008","article-title":"Staphylococcus aureus and atopic dermatitis: a complex and evolving relationship.","volume":"26","author":"Geoghegan","year":"2018","journal-title":"Trends Microbiol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/s13601-020-00338-7","article-title":"IgE autoantibodies and autoreactive T cells and their role in children and adults with atopic dermatitis.","volume":"10","author":"Badloe","year":"2020","journal-title":"Clin Transl Allergy."},{"key":"B34","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/intimm\/dxh248","article-title":"Role of the FcepsilonRI beta-chain ITAM as a signal regulator for mast cell activation with monomeric IgE.","volume":"17","author":"Nunomura","year":"2005","journal-title":"Int Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12016-011-8252-4","article-title":"IgE, mast cells, and eosinophils in atopic dermatitis.","volume":"41","author":"Liu","year":"2011","journal-title":"Clin Rev Allergy Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1016\/j.neuron.2021.07.020","article-title":"Dissecting the precise nature of itch-evoked scratching.","volume":"109","author":"Wimalasena","year":"2021","journal-title":"Neuron."},{"key":"B37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nn.3619","article-title":"Why we scratch an itch: the molecules, cells and circuits of itch.","volume":"17","author":"Bautista","year":"2014","journal-title":"Nat Neurosci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12016-015-8488-5","article-title":"Mediators of chronic pruritus in atopic dermatitis: getting the itch out?","volume":"51","author":"Mollanazar","year":"2016","journal-title":"Clin Rev Allergy Immunol."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-4-29","article-title":"Histamine-induced itch and its relationship with pain.","volume":"4","author":"Shim","year":"2008","journal-title":"Mol Pain."},{"key":"B40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ejphar.2004.03.047","article-title":"Involvement of substance P in scratching behaviour in an atopic dermatitis model.","volume":"491","author":"Ohmura","year":"2004","journal-title":"Eur J Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jaci.2016.02.020","article-title":"The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves.","volume":"138","author":"Feld","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1067\/mai.2003.1554","article-title":"TNF-alpha contributes to the development of allergic rhinitis in mice.","volume":"112","author":"Iwasaki","year":"2003","journal-title":"J Allergy Clin Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nri.2017.118","article-title":"T(H)2 cell development and function.","volume":"18","author":"Walker","year":"2018","journal-title":"Nat Rev Immunol."},{"key":"B44","first-page":"925","article-title":"IL-4 and IL-13 inhibition in atopic dermatitis.","volume":"15","author":"Matsunaga","year":"2016","journal-title":"J Drugs Dermatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1016\/j.jid.2021.04.002","article-title":"Nuclear IL-33 plays an important role in the suppression of FLG, LOR, keratin 1, and keratin 10 by IL-4 and IL-13 in human keratinocytes.","volume":"141","author":"Dai","year":"2021","journal-title":"J Invest Dermatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.cell.2020.12.033","article-title":"A basophil-neuronal axis promotes itch.","volume":"184","author":"Wang","year":"2021","journal-title":"Cell."},{"key":"B47","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice.","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.immuni.2020.06.023","article-title":"The cytokine TGF-\u03b2 induces interleukin-31 expression from dermal dendritic cells to activate sensory neurons and stimulate wound itching.","volume":"53","author":"Xu","year":"2020","journal-title":"Immunity."},{"key":"B49","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jaci.2006.07.015","article-title":"Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis.","volume":"118","author":"Neis","year":"2006","journal-title":"J Allergy Clin Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(94)90879-6","article-title":"Lesional expression of interferon-gamma in atopic eczema.","volume":"343","author":"Grewe","year":"1994","journal-title":"Lancet."},{"key":"B51","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0167-5699(98)01285-7","article-title":"A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis.","volume":"19","author":"Grewe","year":"1998","journal-title":"Immunol Today."},{"key":"B52","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis.","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s40265-020-01335-7","article-title":"New and emerging systemic treatments for atopic dermatitis.","volume":"80","author":"Newsom","year":"2020","journal-title":"Drugs."},{"key":"B54","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov."},{"key":"B55","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","article-title":"Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis.","volume":"158","author":"Drucker","year":"2022","journal-title":"JAMA Dermatol."}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2022.986943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T01:40:47Z","timestamp":1660614047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2022.986943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":55,"alternative-id":["10.3389\/fnut.2022.986943"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2022.986943","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,16]]},"article-number":"986943"}}